Jun 19, 2013 by Brian Orelli, PhDIt's Official: Obesity Is a DiseaseAt least according to the American Medical Association.
Jun 18, 2013 by Brian Orelli, PhDThe FDA Might Pull This Drug From the Market (and Why It Doesn't Matter)Two deaths after patients take Eli Lilly's Zyprexa Relprevv.
Jun 17, 2013 by Brian Orelli, PhDTop Treatments for High CholesterolThere's an investment opportunity, but it's going to take time to play out.
Jun 17, 2013 by Brian Orelli, PhDAbbott Loves Abbott Laboratories StockCompany announces a $3 billion buyback.
Jun 15, 2013 by Brian Orelli, PhDAnother Alzheimer's Disease FailureEli Lilly stops phase 2 trial of BACE inhibitor after some Alzheimer's patients had abnormal liver biochemical tests.
Jun 13, 2013 by Brian Orelli, PhDOvarian Cancer Drug Half Way ThereAmgen's trebananib delays progression, but survival data is key.
Jun 13, 2013 by Brian Orelli, PhDWhy the Pfizer-Teva Settlement Affects the Whole IndustyScore one for the branded drugs.
Jun 11, 2013 by Brian Orelli, PhDDrug Rejected! Let's Rejoice?AVEO's shares go up on the FDA's rejection of tivozanib.
Jun 8, 2013 by Brian Orelli, PhDWhy You Should Care About This Diabetes Drug SagaAre changes to Glaxo's Avandia a sign that the FDA is lightening up?
Jun 7, 2013 by Brian Orelli, PhDNew Obesity Drug Hits the MarketThere's plenty of room for two drugs in an expanding market. Here's what investors need to know.
Jun 4, 2013 by Brian Orelli, PhDThis Pharma Is Trading Like a BiotechBristol-Myers zooms up on clinical trial data.
Jun 3, 2013 by Brian Orelli, PhDDouble Data, Double Stock PriceClovis doubles on ASCO data for two of its drugs.
May 31, 2013 by Brian Orelli, PhD3 Biotech Companies You Should Have Bought This YearBut are they still buys?
May 31, 2013 by Brian Orelli, PhDDividend Investor's ArchnemesisHe's rearing his ugly head in the health-care space.
May 31, 2013 by Brian Orelli, PhDStocks to Buy: Biotechs With Growth PotentialThey're still risky though.
May 31, 2013 by Brian Orelli, PhDStocks to Buy: Biotechs With Binary EventsIf you can tolerate the risk, they're the way to go.
May 30, 2013 by Brian Orelli, PhDWhere to Invest for More Health-Care ExposureThere's something for everyone in the sector.
